亚太地区疫苗佐剂市场预测至 2030 年 – 区域分析 – 按佐剂类别(矿物盐佐剂、乳剂佐剂、脂质体佐剂等)和类型(人用疫苗佐剂和兽用疫苗佐剂)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 88    |    Report Code: BMIRE00031082    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Vaccine Adjuvants Market
2022 年亚太地区疫苗佐剂市场价值为 5.1807 亿美元,预计到 2030 年将达到 15.4643 亿美元;预计 2022 年至 2030 年的复合年增长率为 14.6%。

生物技术和免疫学的进步推动亚太疫苗佐剂市场发展

由于对增强疫苗效力的需求不断增长以及疫苗应用范围扩大到传统传染病之外,疫苗佐剂市场带来了重大机遇。随着新病原体的出现和现有病原体的进化,对能够增强免疫反应并提供更广泛保护的佐剂的需求日益增加。生物技术和免疫学的进步正在推动佐剂配方的创新,为预防和治疗疫苗提供新的解决方案。此外,全球疫苗接种计划的增加和疫苗研究资金的增加也推动了市场增长。专注于开发安全性更高、效果更好的佐剂的公司完全有能力利用这个不断扩大的市场。与研究机构和生物技术公司建立战略伙伴关系和合作可以进一步增加这一充满活力的领域的机会,使其成为一个有前途的投资和发展领域。

亚太疫苗佐剂市场概览

亚太疫苗佐剂市场已细分为中国、日本、印度、澳大利亚、韩国和亚太其他地区。中国公司合作生产佐剂疫苗等战略举措推动了市场的发展。例如,2020 年 4 月,Dynavax Technologies Corporation 宣布与中国生物制药公司 Sinovac 合作开发 CpG 1018 佐剂。 CpG 1018 是 HEPLISAV-B [重组乙肝疫苗,佐剂] 中使用的佐剂,HEPLISAV-B 是美国食品药品监督管理局 (FDA) 批准的一种成人乙肝疫苗,可增强疫苗的免疫反应。因此,中国制造商在采购佐剂疫苗方面的合作和伙伴关系等战略发展是推动市场积极增长的独立因素。

亚太疫苗佐剂市场收入及预测至 2030 年(百万美元)

亚太疫苗佐剂市场细分

亚太疫苗佐剂市场分为佐剂类别、类型和国家。

根据佐剂类别,亚太疫苗佐剂市场分为矿物盐佐剂、乳剂佐剂、脂质体佐剂等。 2022 年,矿物盐佐剂部分占据了亚太疫苗佐剂市场的最大份额。

按类型划分,亚太疫苗佐剂市场分为人用疫苗佐剂和兽用疫苗佐剂。2022 年,人用疫苗佐剂部分占据了亚太疫苗佐剂市场的较大份额。

按国家划分,亚太疫苗佐剂市场分为中国、日本、印度、澳大利亚、韩国和亚太其他地区。2022 年,中国占据了亚太疫苗佐剂市场的主导份额。

Croda International Plc;CSL Ltd;GSK Plc;Hawaii Biotech Inc;InvivoGen SAS;Novavax Inc;Phibro Animal Health Corp;和 SPI Pharma Inc 是亚太疫苗佐剂市场的一些领先公司。

Asia Pacific Vaccine Adjuvants Strategic Insights

Strategic insights for Asia Pacific Vaccine Adjuvants involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-vaccine-adjuvants-market-strategic-framework.webp
Get more information on this report

Asia Pacific Vaccine Adjuvants Report Scope

Report Attribute Details
Market size in 2022 US$ 518.07 Million
Market Size by 2030 US$ 1,546.43 Million
Global CAGR (2022 - 2030) 14.6%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 佐剂类
  • 矿物盐佐剂
  • 乳剂佐剂
  • 脂质体佐剂
By 类型
  • 人用疫苗佐剂
  • 兽用疫苗佐剂
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Croda International Plc
  • CSL Ltd
  • GSK Plc
  • Hawaii Biotech Inc
  • InvivoGen SAS
  • Novavax Inc
  • Phibro Animal Health Corp
  • SPI Pharma Inc
  • Get more information on this report

    Asia Pacific Vaccine Adjuvants Regional Insights

    The regional scope of Asia Pacific Vaccine Adjuvants refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-vaccine-adjuvants-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Vaccine Adjuvants Market

    • Croda International Plc
    • CSL Ltd
    • GSK Plc
    • Hawaii Biotech Inc
    • InvivoGen SAS
    • Novavax Inc
    • Phibro Animal Health Corp
    •  SPI Pharma Inc
    Frequently Asked Questions
    How big is the Asia Pacific Vaccine Adjuvants Market?

    The Asia Pacific Vaccine Adjuvants Market is valued at US$ 518.07 Million in 2022, it is projected to reach US$ 1,546.43 Million by 2030.

    What is the CAGR for Asia Pacific Vaccine Adjuvants Market by (2022 - 2030)?

    As per our report Asia Pacific Vaccine Adjuvants Market, the market size is valued at US$ 518.07 Million in 2022, projecting it to reach US$ 1,546.43 Million by 2030. This translates to a CAGR of approximately 14.6% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Vaccine Adjuvants Market report typically cover these key segments-

  • 佐剂类 (矿物盐佐剂, 乳剂佐剂, 脂质体佐剂)
  • 类型 (人用疫苗佐剂, 兽用疫苗佐剂)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Vaccine Adjuvants Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Vaccine Adjuvants Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Asia Pacific Vaccine Adjuvants Market?

    The Asia Pacific Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Croda International Plc
  • CSL Ltd
  • GSK Plc
  • Hawaii Biotech Inc
  • InvivoGen SAS
  • Novavax Inc
  • Phibro Animal Health Corp
  • SPI Pharma Inc
  • Who should buy this report?

    The Asia Pacific Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.